Entera Bio (NASDAQ:ENTX) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Entera Bio (NASDAQ:ENTX) announced its earnings results on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05), FiscalAI reports.

Entera Bio Price Performance

Shares of NASDAQ ENTX traded up $0.15 during trading hours on Friday, hitting $3.14. 117,978 shares of the company’s stock were exchanged, compared to its average volume of 598,459. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20. The stock has a market capitalization of $546.11 million, a price-to-earnings ratio of -8.97 and a beta of 1.48. The company’s 50-day moving average price is $2.88 and its 200-day moving average price is $1.95.

Analysts Set New Price Targets

ENTX has been the topic of several analyst reports. Lifesci Capital initiated coverage on Entera Bio in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They set an “overweight” rating for the company. Guggenheim began coverage on shares of Entera Bio in a report on Thursday, September 24th. They set a “buy” rating and a $11.00 price objective for the company. Wall Street Zen lowered shares of Entera Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.60.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.